Also, an independent Data Monitoring Committee recommended continuation of the trial without changes after conducting a planned review of blinded safety data.
BLADE-CONQUER is a double-blind, placebo-controlled clinical trial assessing the efficacy and safety of BLD-2660 on lung function and recovery time in hospitalized patients (N=120) with pneumonia due to SARS-CoV-2 infection.
In the study, which started enrollment in May 2020, patients receive up to 10 days of therapy with BLD-2660 or matching placebo dosed orally twice daily on top of standard-of-care therapeutics, including Remdesivir.
CONQUER (COVID Study of New Drug BLD-2660 in Subjects ReQUiring Hospitalization to Evaluate Safety and Response, Clinicaltrials.gov NCT04334460) is a 28-day clinical trial with a 60-day post-study lung function assessment.
The study will measure two primary and multiple secondary outcomes in hospitalized patients with pneumonia (oxygen saturation
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder